Cost-effectiveness of a combined serological screening and treatment study for AG and CagA+ H. pylori infection will likely be higher because more premalignant cancers would be detected among AG patients and fewer individuals with low gastric cancer risk (H. pylori+/CagA– individuals) would receive antibiotic treatment reducing the risk for adverse events and resistant bacteria. The gene discussed is S100A8; the disease is gastric cancer.